




The relative strengths and weaknesses of NRX Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NRX Pharmaceuticals Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 7.2% points. The greatest weakness of NRX Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 68%, being 162% points below the market average of 229%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	8,892	Assets	12,956
Cost of Goods Sold	505	Liabilities	28,893
Intangible Assets	2,718	Expenses	17,449
Liabilities, Current	28,578	Revenues	1,225
Liabilities, Non-Current	0	Stockholders Equity	-15,937
Other Assets	1,283	Net Income	-28,622
Other Compr. Net Income	0	Comprehensive Net Income	-28,622
Other Expenses	106	BaseVar	36,460
Other Liabilities	315	ECR before LimitedLiability	-303%
Other Net Income	-12,398	Economic Capital Ratio	68%
Other Revenues	1,225		
Property and Equipment	63		
Research and Development	3,777		
Selling, General and Administrative Expense	13,061		